VolitionRx (NYSE:VNRX) Earns Sell Rating from Analysts at StockNews.com

StockNews.com started coverage on shares of VolitionRx (NYSE:VNRX) in a research report sent to investors on Wednesday. The brokerage issued a sell rating on the stock.

Separately, Cantor Fitzgerald reaffirmed an overweight rating and set a $2.50 target price on shares of VolitionRx in a report on Thursday, May 16th.

VolitionRx Stock Performance

Shares of VNRX stock opened at $0.64 on Wednesday. The company has a market capitalization of $52.77 million, a price-to-earnings ratio of -1.38 and a beta of 1.13. The company has a 50-day simple moving average of $0.67 and a 200 day simple moving average of $0.81. VolitionRx has a 52 week low of $0.55 and a 52 week high of $1.38.

VolitionRx (NYSE:VNRX) last announced its earnings results on Monday, May 13th. The company reported ($0.10) EPS for the quarter, topping the consensus estimate of ($0.11) by $0.01. The company had revenue of $0.17 million for the quarter, compared to the consensus estimate of $0.27 million. Sell-side analysts forecast that VolitionRx will post -0.31 EPS for the current year.

About VolitionRx

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.